ADMA FY 2021 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$81M+91.7% YoY

Gross Profit

$1M1.4% margin

Operating Income

-$58M-72.1% margin

Net Income

-$72M-88.5% margin

EPS (Diluted)

$-0.61

Cash Flow

Operating Cash Flow

-$112M

Free Cash Flow

-$126M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$276M

Total Liabilities

$135M

Stockholders' Equity

$141M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$81M	$42M	+91.7%
Gross Profit	$1M	-$19M	+106.2%
Operating Income	-$58M	-$65M	+10.1%
Net Income	-$72M	-$76M	+5.4%